Lenz Therapeutics announces FDA acceptance of new drug application for LNZ100 for the treatment of presbyopia

Lenz Therapeutics

21 October 2024 - FDA sets PDUFA target date of 8 August 2025.

Lenz Therapeutics today announced that the US FDA has accepted the Company’s new drug application for LNZ100 for the treatment of presbyopia.

Read Lenz Therapeutics press release 

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Dossier